Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1523035

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1523035

Calcium Channel Blockers Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Calcium Channel Blockers Trends and Forecast

The future of the global calcium channel blockers market looks promising with opportunities in the hypertension, angina, arrhythmia, and hypertrophic cardiomyopathy markets. The global calcium channel blockers market is expected to grow with a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are significant surge in the elderly demographic, increasing accessibility of combined therapeutic approaches, and growing prevalence rate of cardiovascular diseases.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Calcium Channel Blockers by Segment

The study includes a forecast for the global calcium channel blockers by drug class, route of administration, distribution channel, application, and region.

Calcium Channel Blockers Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Phenylalkylamine
  • Benzothizepine
  • Dihydropyridine

Calcium Channel Blockers Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral

Calcium Channel Blockers Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Calcium Channel Blockers Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hypertension
  • Angina
  • Arrhythmia
  • Hypertrophic Cardiomyopathy
  • Others

Calcium Channel Blockers Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Calcium Channel Blockers Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies calcium channel blockers companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the calcium channel blockers companies profiled in this report include-

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo

Calcium Channel Blockers Market Insights

Lucintel forecasts that dihydropyridine will remain the largest segment over the forecast period due to its increasing adoption for treating hypertension.

Within this market, hypertension will remain the largest segment.

North America will remain the largest segment over the forecast period due to high prevalence of cardiovascular diseases and rising aging population in the region.

Features of the Global Calcium Channel Blockers Market

Market Size Estimates: Calcium channel blockers market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Calcium channel blockers market size by various segments, such as by drug class, route of administration, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Calcium channel blockers market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, route of administration, distribution channels, application, and regions for the calcium channel blockers market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the calcium channel blockers market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for calcium channel blockers market?

Answer: The global calcium channel blockers market is expected to grow with a CAGR of 5.4% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the calcium channel blockers market?

Answer: The major drivers for this market are significant surge in the elderly demographic, increasing accessibility of combined therapeutic approaches and growing prevalence rate of cardiovascular diseases.

Q3. What are the major segments for calcium channel blockers market?

Answer: The future of the calcium channel blockers market looks promising with opportunities in the hypertension, angina, arrhythmia, and hypertrophic cardiomyopathy markets.

Q4. Who are the key calcium channel blockers market companies?

Answer: Some of the key calcium channel blockers companies are as follows:

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo

Q5. Which calcium channel blockers market segment will be the largest in future?

Answer: Lucintel forecasts that dihydropyridine will remain the largest segment over the forecast period due to its increasing adoption for treating hypertension.

Q6. In calcium channel blockers market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to high prevalence of cardiovascular diseases and rising aging population in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the calcium channel blockers market by drug class (phenylalkylamine, benzothizepine, and dihydropyridine), route of administration (oral and parenteral), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (hypertension, angina, arrhythmia, hypertrophic cardiomyopathy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Calcium Channel Blockers Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Calcium Channel Blockers Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Calcium Channel Blockers Market by Drug Class
    • 3.3.1: Phenylalkylamine
    • 3.3.2: Benzothizepine
    • 3.3.3: Dihydropyridine
  • 3.4: Global Calcium Channel Blockers Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Parenteral
  • 3.5: Global Calcium Channel Blockers Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: Online Pharmacies
  • 3.6: Global Calcium Channel Blockers Market by Application
    • 3.6.1: Hypertension
    • 3.6.2: Angina
    • 3.6.3: Arrhythmia
    • 3.6.4: Hypertrophic Cardiomyopathy
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Calcium Channel Blockers Market by Region
  • 4.2: North American Calcium Channel Blockers Market
    • 4.2.1: North American Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.2.2: North American Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.3: European Calcium Channel Blockers Market
    • 4.3.1: European Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.3.2: European Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.4: APAC Calcium Channel Blockers Market
    • 4.4.1: APAC Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.4.2: APAC Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.5: ROW Calcium Channel Blockers Market
    • 4.5.1: ROW Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.5.2: ROW Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Calcium Channel Blockers Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Calcium Channel Blockers Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Calcium Channel Blockers Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Calcium Channel Blockers Market by Application
    • 6.1.5: Growth Opportunities for the Global Calcium Channel Blockers Market by Region
  • 6.2: Emerging Trends in the Global Calcium Channel Blockers Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Calcium Channel Blockers Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Calcium Channel Blockers Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Teva Pharmaceutical Industries
  • 7.3: Bausch Health Company
  • 7.4: Novartis
  • 7.5: AstraZeneca
  • 7.6: Merck
  • 7.7: GSK
  • 7.8: Bayer
  • 7.9: Sun Pharmaceutical Industries
  • 7.10: Daiichi Sankyo
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!